GLP-1 drugs | Nelson Advisors

Nelson Advisors Big Questions in HealthTech Series: Are GLP-1 drugs an existential threat or a Growth Catalyst for Digital Health?

The rapid proliferation of glucagon-like peptide-1 (GLP-1) receptor agonists and multi-target incretin mimetics represents the most disruptive structural force in modern healthcare since the emergence of digital health itself. Originally developed for type 2 diabetes management, these pharmacological interventions, including semaglutide and dual GLP-1/GIP agonists like tirzepatide, have expanded into chronic weight management, cardiovascular risk reduction, and metabolic dy

Nelson Advisors

Aug 8

Add a title here. Make it bold and impactful. Click to edit.

Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV.